Atorvastatin prevents hearing impairment in the presence of hyperlipidemia

Area of Science:

• Oto-science
• Biochemistry
• Pharmacology

Background:

• Hyperlipidemia is a known risk factor for sensorineural hearing loss.
• The precise biological mechanisms linking hyperlipidemia to cochlear damage remain unclear.
• Previous human studies suggest hyperlipidemia medications may preserve hearing.

Purpose of the Study:

• To investigate the relationship between hyperlipidemia and hearing impairment.
• To evaluate the hearing preservation effects of atorvastatin in a mouse model.
• To elucidate the molecular pathways involved in hyperlipidemia-induced hearing loss.

Main Methods:

• Utilized a diet-induced obesity (DIO) mouse model to induce hyperlipidemia.
• Assessed hearing function, reactive oxygen species (ROS) levels, and hair cell survival.
• Measured levels of key proteins like pAKT and superoxide dismutase 2 (SOD2).
• Investigated the role of the PI3K-pAKT pathway and Nrf2-mediated antioxidant responses.

Main Results:

• DIO mice exhibited significant hearing impairment, increased ROS, and hair cell death.
• Atorvastatin treatment significantly prevented these hearing deficits and cellular damage.
• Atorvastatin increased the expression of Nrf2 and antioxidant genes, enhancing mitochondrial function.
• The drug activated the PI3K-pAKT pathway, reducing oxidative stress and apoptosis.

Conclusions:

• Hyperlipidemia contributes to hearing impairment through oxidative stress and mitochondrial dysfunction in the cochlea.
• Atorvastatin demonstrates a protective effect against hearing loss in a hyperlipidemic mouse model.
• Atorvastatin preserves hearing by restoring redox balance and activating protective cellular pathways.